Previous 10 |
Bio-Path Holdings (NASDAQ: BPTH ) +55% on positive prexigebersen data. More news on: Bio-Path Holdings, Inc., Abercrombie & Fitch, China Automotive Systems, Inc., Stocks on the move, Read more ...
Idera Pharmaceuticals (NASDAQ: IDRA ) has completed enrollment in the Phase 2 expansion of ILLUMINATE-204 evaluating the combination of TLR9 agonist tilsotolimod and Bristol-Myers Squibb's (NYSE: BMY ) Yervoy (ipilimumab) in melanoma patients who failed to response to PD-1 inhibitor ther...
- Results from the Phase 2 Expansion of ILLUMINATE-204 anticipated to be reported in the 4 th Quarter of 2019 – - December 2018 Interim Update of 34 efficacy evaluable patients demonstrated 32.4% achieved partial response (PR) or better; 76.5% of patients achieved diseas...
News, Short Squeeze, Breakout and More Instantly...
Idera Pharmaceuticals Inc. Company Name:
IDRA Stock Symbol:
NASDAQ Market:
Idera Pharmaceuticals Inc. Website:
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWI...
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results fo...
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) ...